Professor | Yifu He | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yifu He
Contact Information	yifuhe@fsyy.ustc.edu.cn
Language ability	Chinese, English
Province	Anhui

Upload Avatar (500 x 500)

Name

Yifu He

Contact Information

yifuhe@fsyy.ustc.edu.cn

Language ability

Chinese, English

Province

Anhui

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Mayo Clinic College of Medicine
Academic Background & Achievements	1992.9-1997.7 Bachelor of Medicine: Shandong Medical University 2003.9-2006.7 Master of Oncology: Sun Yat-sen University 2006.9-2009.7 Doctor of Clinical Pharmacology: Anhui Medical University 2019.5-2019.7 Advanced Study: Florida, USA Published over 20 SCI papers Received Anhui Provincial Natural Science Foundation (2 projects) Received Anhui Provincial Key Research and Development Plan Project (1 project) Received Hefei Science and Technology Bureau Project (1 project) Supervised 3 doctoral and 10 master's students Received Third Prize of Provincial Science and Technology Progress
Work Experience	1997.9-2002.11 - Anhui Provincial Hospital - Resident Physician 2002.12-2008.11 - Anhui Provincial Hospital - Attending Physician 2008.12-2016.11 - Anhui Provincial Hospital - Associate Chief Physician, Master's Supervisor, Associate Professor 2016.12-2017.11 - Anhui Provincial Hospital - Chief Physician, Master's Supervisor, Associate Professor 2017.12-present - The First Affiliated Hospital of USTC - Chief Physician, Doctoral Supervisor, Professor, Administrative Deputy Director
Awards	Third Prize of Provincial Science and Technology Progress: Detail not mentioned

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Mayo Clinic College of Medicine

Academic Background & Achievements

1992.9-1997.7 Bachelor of Medicine: Shandong Medical University
2003.9-2006.7 Master of Oncology: Sun Yat-sen University
2006.9-2009.7 Doctor of Clinical Pharmacology: Anhui Medical University
2019.5-2019.7 Advanced Study: Florida, USA
Published over 20 SCI papers
Received Anhui Provincial Natural Science Foundation (2 projects)
Received Anhui Provincial Key Research and Development Plan Project (1 project)
Received Hefei Science and Technology Bureau Project (1 project)
Supervised 3 doctoral and 10 master's students
Received Third Prize of Provincial Science and Technology Progress

Work Experience

1997.9-2002.11 - Anhui Provincial Hospital - Resident Physician
2002.12-2008.11 - Anhui Provincial Hospital - Attending Physician
2008.12-2016.11 - Anhui Provincial Hospital - Associate Chief Physician, Master's Supervisor, Associate Professor
2016.12-2017.11 - Anhui Provincial Hospital - Chief Physician, Master's Supervisor, Associate Professor
2017.12-present - The First Affiliated Hospital of USTC - Chief Physician, Doctoral Supervisor, Professor, Administrative Deputy Director

Awards

Third Prize of Provincial Science and Technology Progress: Detail not mentioned

Areas of Focus	Diagnosis and treatment of gastrointestinal tumors Molecular targeted therapy for gastrointestinal tumors Biological immunotherapy for gastrointestinal tumors
Publications	Tumor-associated mesenchymal stem cells promote hepatocellular carcinoma metastasis via a DNM3OS/KDM6B/TIAM1 axis., Wang W, Wang Q, Huang DB, Sun QK, Wu SS, Zhao YJ, Jia W, Hu DS, He YF(corresponding), 2021 Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway., Wang W, Shen XB, Huang DB, Jia W, Liu WB, He YF(corresponding), 2019 Knockdown of CENPK inhibits cell growth and facilitates apoptosis via PTEN-PI3K-AKT signalling pathway in gastric cancer., Shnsheng Wu, Lulu Cao, Lihong Ke, Ying Yan, Huiqin luo, Xiaoxiu Hu, Jiayu Niu, Huimin Li, Huijun Xu, Wenjun Chen, Yueyin Pan, Yifu He, 2021 Limb-bud and heart as a novel biomarker for gastric intestinal type adenocarcinoma., Wu SS, Chen J, Yan Y, Luo HQ, Chen WJ, He YF(corresponding), 2020 Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China., Peng W, Zhang F, Wang Z, Li D, He Y(共同第一), Ning Z, Sheng L, Wang J, Xia X, Yu C, Wang Z, Zhao Y, Liang H, Hu B, Sun C, Wang D, Cheng Y, Pan M, Xia L, Guo X, Zhang Y, Hu Z, Li X, Lu L, Zhang J, Qian H, Xie H, Sun G, 2020 A six-microRNA signature to predict outcomes of patients with gastric cancer., Chen J, Hu B, Wang W, Qian XJ, Shan BJ, He YF(corresponding), 2019 Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor., Luo HQ, He YF(corresponding), Chen WJ, Yan Y, Wu SS, Hu XX, Ke LH, Niu JY, Li HM, Xu HJ, 2019 Serological and Molecular Characterization of Hepatitis B Virus Infection in Gastric Cancer., Mengge Li, Shusheng Wu, Huiqin Luo, Jiayu Niu, Ying Yan, Yuan Fang, Lihong Ke, Wenju Chen, Huijun Xu, Huimin Li, Xiaoxiu Hu, Lulu Cao, Yaolin Chen, Hong Tu, Yifu He, 2022 Combining Clinicopathology, IVIM-DWI and Texture Parameters for a Nomogram to Predict Treatment Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients., Rixin Su, Shusheng Wu, Hao Shen, Yaolin Chen, Jingya Zhu, Yu Zhang, Haodong Jia, Mengge Li, Wenju Chen, Yifu He, Fei Gao, 2022 Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study., Ying Yan, Huimin Li, Shusheng Wu, Gang Wang, Huiqin Luo, Jiayu Niu, Lulu Cao, Xiaoxiu Hu, Huijun Xu, Wei Jia, Yubei Sun, Yiwei Yao, Wenju Chen, Lihong Ke, Bing Hu, Chushu Ji, Yancai Sun, Jian Chen, Mengge Li, Yifu He, 2022 A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer., Hao Shen, Shusheng Wu, Rixin Su, Yaolin Chen, Yifu He, 2022 Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients., Rixin Su, Jingya Zhu, Shusheng Wu, Huiqin Luo, Yifu He, 2022 Pretreatment lymphocyte-monocyte ratio (LMR) as a superior predictor of short-term progression outcomes in patients with gastric cancer receiving second- and later-line apatinib regimens., Hao Shen, Wenxi Dang, Rixin Su, Zhihua Zhang, Shusheng Wu, Mengge Li, Xudong liu, Yifu He, 2023 Modification of m5C regulators in sarcoma can guide different immune infiltrations as well as immunotherapy., Shusheng Wu, Mengge Li, Rixin Su, Hao Shen, Yifu He, YangFan Zhou, 2023 Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial., Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators, 2023

Areas of Focus

Diagnosis and treatment of gastrointestinal tumors
Molecular targeted therapy for gastrointestinal tumors
Biological immunotherapy for gastrointestinal tumors

Publications

Tumor-associated mesenchymal stem cells promote hepatocellular carcinoma metastasis via a DNM3OS/KDM6B/TIAM1 axis., Wang W, Wang Q, Huang DB, Sun QK, Wu SS, Zhao YJ, Jia W, Hu DS, He YF(corresponding), 2021
Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway., Wang W, Shen XB, Huang DB, Jia W, Liu WB, He YF(corresponding), 2019
Knockdown of CENPK inhibits cell growth and facilitates apoptosis via PTEN-PI3K-AKT signalling pathway in gastric cancer., Shnsheng Wu, Lulu Cao, Lihong Ke, Ying Yan, Huiqin luo, Xiaoxiu Hu, Jiayu Niu, Huimin Li, Huijun Xu, Wenjun Chen, Yueyin Pan, Yifu He, 2021
Limb-bud and heart as a novel biomarker for gastric intestinal type adenocarcinoma., Wu SS, Chen J, Yan Y, Luo HQ, Chen WJ, He YF(corresponding), 2020
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China., Peng W, Zhang F, Wang Z, Li D, He Y(共同第一), Ning Z, Sheng L, Wang J, Xia X, Yu C, Wang Z, Zhao Y, Liang H, Hu B, Sun C, Wang D, Cheng Y, Pan M, Xia L, Guo X, Zhang Y, Hu Z, Li X, Lu L, Zhang J, Qian H, Xie H, Sun G, 2020
A six-microRNA signature to predict outcomes of patients with gastric cancer., Chen J, Hu B, Wang W, Qian XJ, Shan BJ, He YF(corresponding), 2019
Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor., Luo HQ, He YF(corresponding), Chen WJ, Yan Y, Wu SS, Hu XX, Ke LH, Niu JY, Li HM, Xu HJ, 2019
Serological and Molecular Characterization of Hepatitis B Virus Infection in Gastric Cancer., Mengge Li, Shusheng Wu, Huiqin Luo, Jiayu Niu, Ying Yan, Yuan Fang, Lihong Ke, Wenju Chen, Huijun Xu, Huimin Li, Xiaoxiu Hu, Lulu Cao, Yaolin Chen, Hong Tu, Yifu He, 2022
Combining Clinicopathology, IVIM-DWI and Texture Parameters for a Nomogram to Predict Treatment Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients., Rixin Su, Shusheng Wu, Hao Shen, Yaolin Chen, Jingya Zhu, Yu Zhang, Haodong Jia, Mengge Li, Wenju Chen, Yifu He, Fei Gao, 2022
Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study., Ying Yan, Huimin Li, Shusheng Wu, Gang Wang, Huiqin Luo, Jiayu Niu, Lulu Cao, Xiaoxiu Hu, Huijun Xu, Wei Jia, Yubei Sun, Yiwei Yao, Wenju Chen, Lihong Ke, Bing Hu, Chushu Ji, Yancai Sun, Jian Chen, Mengge Li, Yifu He, 2022
A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer., Hao Shen, Shusheng Wu, Rixin Su, Yaolin Chen, Yifu He, 2022
Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients., Rixin Su, Jingya Zhu, Shusheng Wu, Huiqin Luo, Yifu He, 2022
Pretreatment lymphocyte-monocyte ratio (LMR) as a superior predictor of short-term progression outcomes in patients with gastric cancer receiving second- and later-line apatinib regimens., Hao Shen, Wenxi Dang, Rixin Su, Zhihua Zhang, Shusheng Wu, Mengge Li, Xudong liu, Yifu He, 2023
Modification of m5C regulators in sarcoma can guide different immune infiltrations as well as immunotherapy., Shusheng Wu, Mengge Li, Rixin Su, Hao Shen, Yifu He, YangFan Zhou, 2023
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial., Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators, 2023

Gastrointestinal Tumors Diagnosis Treatment Molecular Targeting Biological Therapy Immunotherapy Esophageal Cancer Gastric Cancer Liver Cancer Pancreatic Cancer

Junbo Ge - University of Science and Technology of China

Jianping Weng - University of Science and Technology of China

Jiong Shi - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us